Cannabidiol and neuroprotection: evidence from preclinical studies (2017)
- Authors:
- USP affiliated authors: HALLAK, JAIME EDUARDO CECILIO - FMRP ; ZUARDI, ANTONIO WALDO - FMRP ; CRIPPA, JOSÉ ALEXANDRE DE SOUZA - FMRP
- Unidade: FMRP
- DOI: 10.1016/B978-0-12-800756-3.00095-8
- Subjects: CANNABIS; ANTIOXIDANTES; DOENÇA DE ALZHEIMER; ANÓXIA; ISQUEMIA; FERRO; MODELOS ANIMAIS
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Handbook of Cannabis and related pathologies: biology, pharmacology, diagnosis, and treatment
- Volume/Número/Paginação/Ano: 1143 p.
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
SCHRÖDER, N. et al. Cannabidiol and neuroprotection: evidence from preclinical studies. Handbook of Cannabis and related pathologies: biology, pharmacology, diagnosis, and treatment. Tradução . London: Elsevier, 2017. p. 1143 . Disponível em: https://doi.org/10.1016/B978-0-12-800756-3.00095-8. Acesso em: 19 abr. 2024. -
APA
Schröder, N., Silva, V. K., Hallak, J. E. C., Zuardi, A. W., & Crippa, J. A. de S. (2017). Cannabidiol and neuroprotection: evidence from preclinical studies. In Handbook of Cannabis and related pathologies: biology, pharmacology, diagnosis, and treatment (p. 1143 ). London: Elsevier. doi:10.1016/B978-0-12-800756-3.00095-8 -
NLM
Schröder N, Silva VK, Hallak JEC, Zuardi AW, Crippa JA de S. Cannabidiol and neuroprotection: evidence from preclinical studies [Internet]. In: Handbook of Cannabis and related pathologies: biology, pharmacology, diagnosis, and treatment. London: Elsevier; 2017. p. 1143 .[citado 2024 abr. 19 ] Available from: https://doi.org/10.1016/B978-0-12-800756-3.00095-8 -
Vancouver
Schröder N, Silva VK, Hallak JEC, Zuardi AW, Crippa JA de S. Cannabidiol and neuroprotection: evidence from preclinical studies [Internet]. In: Handbook of Cannabis and related pathologies: biology, pharmacology, diagnosis, and treatment. London: Elsevier; 2017. p. 1143 .[citado 2024 abr. 19 ] Available from: https://doi.org/10.1016/B978-0-12-800756-3.00095-8 - Cannabidiol: an anxiolytic or an antipsychotic new drug?
- Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study
- Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizopherenia: an update
- Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus
- Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders
- Administration of harmine and imipramine alters creatine kinase and mitochondrial respiratory chain activities in the rat brain
- Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implication for neuroprotection
- Cannabidiol prevents motor and cognitive impairments induced by reserpine in rats
- Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system
- Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: reversal by cannabidiol
Informações sobre o DOI: 10.1016/B978-0-12-800756-3.00095-8 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas